SG11202111132WA - Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one - Google Patents
Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-oneInfo
- Publication number
- SG11202111132WA SG11202111132WA SG11202111132WA SG11202111132WA SG11202111132WA SG 11202111132W A SG11202111132W A SG 11202111132WA SG 11202111132W A SG11202111132W A SG 11202111132WA SG 11202111132W A SG11202111132W A SG 11202111132WA SG 11202111132W A SG11202111132W A SG 11202111132WA
- Authority
- SG
- Singapore
- Prior art keywords
- chloro
- diazacyclotetradecin
- metheno
- pyrazolo
- hexahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962832614P | 2019-04-11 | 2019-04-11 | |
PCT/US2020/027655 WO2020210613A1 (en) | 2019-04-11 | 2020-04-10 | Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111132WA true SG11202111132WA (en) | 2021-11-29 |
Family
ID=70457148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111132WA SG11202111132WA (en) | 2019-04-11 | 2020-04-10 | Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220144836A1 (en) |
EP (2) | EP3953334B1 (en) |
JP (1) | JP2022526659A (en) |
KR (1) | KR20220045105A (en) |
CN (1) | CN114375290A (en) |
AR (1) | AR118649A1 (en) |
AU (1) | AU2020272973A1 (en) |
BR (1) | BR112021020368A2 (en) |
CA (1) | CA3132365A1 (en) |
EA (1) | EA202192807A1 (en) |
IL (1) | IL287102A (en) |
MX (1) | MX2021012286A (en) |
SG (1) | SG11202111132WA (en) |
TW (1) | TW202104188A (en) |
WO (1) | WO2020210613A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115427557A (en) | 2020-04-10 | 2022-12-02 | 科德克希思公司 | Engineered transaminase polypeptides |
TW202229280A (en) * | 2020-10-12 | 2022-08-01 | 美商必治妥美雅史谷比公司 | A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2013010576A (en) * | 2011-03-15 | 2014-03-12 | Abbvie Inc | Nuclear hormone receptor modulators. |
JP6464176B2 (en) | 2014-01-31 | 2019-02-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Macrocycles as factor XIA inhibitors with aromatic P2 'groups |
NO2721243T3 (en) * | 2014-10-01 | 2018-10-20 | ||
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
CN105294496A (en) * | 2015-09-28 | 2016-02-03 | 中山大学 | Preparation method of citalopram intermediate |
WO2018133793A1 (en) * | 2017-01-18 | 2018-07-26 | 广东东阳光药业有限公司 | Blood coagulation factor xia inhibitor and uses thereof |
KR20220002966A (en) * | 2019-04-16 | 2022-01-07 | 메드샤인 디스커버리 아이엔씨. | Macrocyclic derivatives as factor XIa inhibitors |
JP7286001B2 (en) * | 2019-07-23 | 2023-06-02 | メッドシャイン ディスカバリー インコーポレイテッド | Macrocyclic derivatives as factor XIa inhibitors |
US20230159904A1 (en) * | 2020-04-10 | 2023-05-25 | Codexis, Inc | Carboxyesterase polypeptides for kinetic resolution |
-
2020
- 2020-04-10 US US17/602,059 patent/US20220144836A1/en active Pending
- 2020-04-10 BR BR112021020368A patent/BR112021020368A2/en unknown
- 2020-04-10 CN CN202080041935.8A patent/CN114375290A/en active Pending
- 2020-04-10 AU AU2020272973A patent/AU2020272973A1/en active Pending
- 2020-04-10 CA CA3132365A patent/CA3132365A1/en active Pending
- 2020-04-10 SG SG11202111132WA patent/SG11202111132WA/en unknown
- 2020-04-10 MX MX2021012286A patent/MX2021012286A/en unknown
- 2020-04-10 JP JP2021559890A patent/JP2022526659A/en active Pending
- 2020-04-10 EP EP20721374.5A patent/EP3953334B1/en active Active
- 2020-04-10 EA EA202192807A patent/EA202192807A1/en unknown
- 2020-04-10 KR KR1020217036807A patent/KR20220045105A/en unknown
- 2020-04-10 TW TW109112263A patent/TW202104188A/en unknown
- 2020-04-10 WO PCT/US2020/027655 patent/WO2020210613A1/en unknown
- 2020-04-10 EP EP23169596.6A patent/EP4234555A3/en active Pending
- 2020-04-13 AR ARP200101024A patent/AR118649A1/en unknown
-
2021
- 2021-10-07 IL IL287102A patent/IL287102A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR118649A1 (en) | 2021-10-20 |
EP4234555A2 (en) | 2023-08-30 |
MX2021012286A (en) | 2022-04-06 |
KR20220045105A (en) | 2022-04-12 |
EA202192807A1 (en) | 2022-02-24 |
CN114375290A (en) | 2022-04-19 |
WO2020210613A1 (en) | 2020-10-15 |
EP3953334B1 (en) | 2023-11-22 |
JP2022526659A (en) | 2022-05-25 |
AU2020272973A1 (en) | 2021-12-02 |
US20220144836A1 (en) | 2022-05-12 |
IL287102A (en) | 2021-12-01 |
EP4234555A3 (en) | 2024-01-03 |
TW202104188A (en) | 2021-02-01 |
CA3132365A1 (en) | 2020-10-15 |
EP3953334A1 (en) | 2022-02-16 |
BR112021020368A2 (en) | 2021-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287102A (en) | Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one | |
IL291471A (en) | Pyrido[3,2-d]pyrimidine compounds as immunomodulators | |
IL308438A (en) | Pyrido[4,3-d]pyrimidine compounds capable of inhibiting kras mutant proteins | |
MX2021011438A (en) | Imidazopyrrolopyridine as inhibitors of the jak family of kinases. | |
ZA202204206B (en) | Pesticidally active fused bicyclic heteroaromatic compounds | |
SI1725544T1 (en) | 3-?á4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL?å-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | |
GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
FI3689865T3 (en) | Novel amino pyrimidine derivatives | |
NZ626394A (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
JP2014513139A5 (en) | ||
EP3997087A4 (en) | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | |
GEP20227344B (en) | Pyrimidine compound as jak kinase inhibitor | |
ZA202101735B (en) | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto | |
MX2017015257A (en) | CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1, 2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND. | |
GEP20197050B (en) | Solid state forms of fused heteroaromatic pyrrolidinones | |
ZA201002214B (en) | 3-methyl-2-((2s)-2-(4-(3-methyl-l,2,4-0xadiazol-5-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3h)-one as tau protein kinase inhibitor | |
MX2017014438A (en) | Crystals of azabicyclic compound. | |
NZ629411A (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
MX2021012849A (en) | A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor. | |
IL273396A (en) | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as cdk inhibitors | |
IL289456A (en) | Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds | |
MX2020002505A (en) | Cycloolefin substituted heteroaromatic compounds and their use. | |
PH12020551465A1 (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds | |
UA88701C2 (en) | Quinoline derivatives as antibacterial agents | |
IL291721A (en) | Crystalline forms of 5-bromo-2,6-di(1 h-pyrazol-1-yl)pyrimidin-4-amine and new salts |